Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 30;20(17):4262.
doi: 10.3390/ijms20174262.

Cyclo-Oxygenase (COX) Inhibitors and Cardiovascular Risk: Are Non-Steroidal Anti-Inflammatory Drugs Really Anti-Inflammatory?

Affiliations
Review

Cyclo-Oxygenase (COX) Inhibitors and Cardiovascular Risk: Are Non-Steroidal Anti-Inflammatory Drugs Really Anti-Inflammatory?

Shanzana Khan et al. Int J Mol Sci. .

Abstract

Cyclo-oxygenase (COX) inhibitors are among the most commonly used drugs in the western world for their anti-inflammatory and analgesic effects. However, they are also well-known to increase the risk of coronary events. This area is of renewed significance given alarming new evidence suggesting this effect can occur even with acute usage. This contrasts with the well-established usage of aspirin as a mainstay for cardiovascular prophylaxis, as well as overwhelming evidence that COX inhibition induces vasodilation and is protective for vascular function. Here, we present an updated review of the preclinical and clinical literature regarding the cardiotoxicity of COX inhibitors. While studies to date have focussed on the role of COX in influencing renal and vascular function, we suggest an interaction between prostanoids and T cells may be a novel factor, mediating elevated cardiovascular disease risk with NSAID use.

Keywords: T cells; adaptive immunity; coronary disease; cyclo-oxygenase; immune-mediated hypertension; prostanoids; vascular dysfunction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
COX inhibition decreases or increases BP through inhibition of renal COX-1 or COX-2 respectively. However, the overwhelming effect of COX inhibition in the vasculature is vasodilatory. Finally, we have shown systemic COX inhibition may increase BP through activation of T cells and promotion of their infiltration into cardiovascular organs.

Similar articles

Cited by

References

    1. Qi Z., Hao C.M., Langenbach R.I., Breyer R.M., Redha R., Morrow J.D., Breyer M.D. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J. Clin. Investig. 2002;110:61–69. doi: 10.1172/JCI0214752. - DOI - PMC - PubMed
    1. Bally M., Dendukuri N., Rich B., Nadeau L., Helin-Salmivaara A., Garbe E., Brophy J.M. Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data. BMJ. 2017;357:j1909. doi: 10.1136/bmj.j1909. - DOI - PMC - PubMed
    1. Khan S.I., Shihata W.A., Andrews K.L., Lee M.K.S., Moore X.L., Jefferis A.M., Vinh A., Gaspari T., Dragoljevic D., Jennings G.L., et al. Effects of high- and low-dose aspirin on adaptive immunity and hypertension in the stroke-prone spontaneously hypertensive rat. FASEB J. 2019;33:1510–1521. doi: 10.1096/fj.201701498RR. - DOI - PubMed
    1. Guzik T.J., Hoch N.E., Brown K.A., McCann L.A., Rahman A., Dikalov S., Goronzy J., Weyand C., Harrison D.G. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 2007;204:2449–2460. doi: 10.1084/jem.20070657. - DOI - PMC - PubMed
    1. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 2000;343:1520–1528. doi: 10.1056/NEJM200011233432103. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources

-